CELL INTELLIGENCE · 肿瘤细胞治疗研究

The combination of chemotherapy and radiation therapy (RT) can significantly enhance anticancer efficacy, and nanoparticle-based systems that function as both radiosensitizers and drug carriers offer a promising strategy for multimodal cancer treatment. Here, we developed a core-shell nanoplatform composed of a bismuth ferrite (BiFeO 3 , BFO) core and a mesoporous silica shell, loaded with doxorubicin (DOX) and coated with mesenchymal stem cell-derived exosomes to form a biomimetic construct (Exo-BFO-Si-DOX). The system was further functionalized with a mucin-1 (MUC-1) aptamer (Apt-Exo-BFO-Si-DOX) to enable targeted delivery to MUC-1-overexpressing cancer cells. The BFO core enhanced RT efficacy while enabling dual-modality magnetic resonance imaging (MRI) and computed tomography (CT). The nanoplatform exhibited high DOX encapsulation efficiency and suitable loading capacity, and the exosome coating provided controlled drug release under physiological conditions. In vitro experiments demonstrated strong chemoradiation efficacy and apoptosis induction in SK-MES-1 and A549 non-small cell lung cancer (NSCLC) cells, with apoptosis rates of 52.10% and 64.28%, respectively. Notably, Apt-Exo-BFO-Si-DOX exhibited enhanced cytotoxicity, apoptosis induction, and radiosensitization compared with Exo-BFO-Si-DOX. In vivo MRI and CT imaging of SK-MES-1 tumor-bearing nude mice confirmed efficient tumor accumulation at 6 h post-injection, with significantly higher uptake for the targeted platform compared to its non-targeted counterpart (CT: 52.50 vs. 43.50 HU; MRI: 50.60 vs. 64.50 signal intensity). Overall, these results indicate that Apt-Exo-BFO-Si-DOX is a promising multifunctional nanoplatform for synergistic chemoradiotherapy and dual MR/CT imaging of cancer.